Evidence map›Paper›PMID 32721130›Full record

ReviewCancer reports (Hoboken, N.J.)2019

Soluble immune checkpoint molecules: Serum markers for cancer diagnosis and prognosis.

Rituparna Chakrabarti, Bhavya Kapse, Gayatri Mukherjee

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancer reports (Hoboken, N.J.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
1.8field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 48 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Diagnostic and Staging Value of Serum Angiotensin-Converting Enzyme in Sarcoidosis.Computational and mathematical methods in medicine · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Rituparna ChakrabartiSchool of Medical Science and Technology, Indian Institute of Technology Kharagpur, Kharagpur, India.
Bhavya KapseDepartment of Biotechnology, Indian Institute of Technology Kharagpur, Kharagpur, India.
Gayatri MukherjeeSchool of Medical Science and Technology, Indian Institute of Technology Kharagpur, Kharagpur, India.ORCID 0000-0003-3199-7213
Indian Institute of Technology Kharagpur · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWith the recent advances in the understanding of the interaction of the immune system with developing tumor, it has become imperative to consider the immunological parameters for both cancer diagnosis and disease prognosis. Additionally, in the era of emerging immunotherapeutic strategies in cancer, it is very important to follow the treatment outcome and also to predict the correct immunotherapeutic strategy in individual patients. There being enormous heterogeneity among tumors at different sites or between primary and metastatic tumors in the same individual, or interpatient heterogeneity, it is very important to study the tumor-immune interaction in the tumor microenvironment and beyond. Importantly, molecular tools and markers identified for such studies must be suitable for monitoring in a noninvasive manner. RECENT

findingsRecent studies have shown that the immune checkpoint molecules play a key role in the development and progression of tumors. In-depth studies of these molecules have led to the development of most of the cancer immunotherapeutic reagents that are currently either in clinical use or under different phases of clinical trials. Interestingly, many of these cell surface molecules undergo alternative splicing to produce soluble isoforms, which can be tracked in the serum of patients.

conclusionsSeveral studies demonstrate that the serum levels of these soluble isoforms could be used as noninvasive markers for cancer diagnosis and disease prognosis or to predict patient response to specific therapeutic strategies.

Indexed as

Alternative SplicingAntineoplastic Agents, ImmunologicalBiomarkers, TumorDisease ProgressionDrug Resistance, NeoplasmHumansImmune Checkpoint ProteinsNeoplasmsPrognosisProgression-Free SurvivalProtein IsoformsTumor MicroenvironmentAntineoplastic Agents, ImmunologicalBiomarkers, TumorImmune Checkpoint ProteinsProtein Isoformscancerimmune checkpoint moleculesimmunotherapyprognostic and diagnostic markerssoluble isoforms

Identifiers

PMID32721130
PMCPMC7941475
OpenAlexW2914835175

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.